How to access Soliris from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), or neuromyelitis optica spectrum disorder (NMOSD) may receive a prescription for Soliris (eculizumab) from their treating haematologist, nephrologist, or neurologist. Soliris is FDA-approved in the United States and manufactured by Alexion (AstraZeneca Rare Disease). It is a humanised monoclonal antibody that inhibits terminal complement activation. Because Soliris is a complement inhibitor, access is coordinated with the manufacturer's controlled-distribution model and physician training/registration expectations; the named-patient pathway respects those parameters while solving supply and formulary gaps. In the UAE, Soliris may be available in limited tertiary settings but not broadly stocked, which is why your physician may be navigating a named-patient import pathway with you.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
Ask about Soliris in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Soliris is administered as an IV infusion every two weeks after an induction period. It carries a US boxed warning regarding life-threatening meningococcal infections, which is why meningococcal vaccination (or appropriate antibiotic prophylaxis if vaccination is not feasible in time) is a gating step before therapy begins, as is enrolment in the US REMS program. Internationally, equivalent manufacturer risk-minimisation measures apply. Your treating physician confirms diagnosis, vaccination status, prior therapy history, and the monitoring plan per FDA labeling.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Soliris legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework. The pathway allows an Emirati-licensed physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.
For eculizumab specifically, international access respects the manufacturer's controlled-distribution program and the physician-registration expectations tied to the meningococcal-infection risk profile.
How the pathway works, step by step
- Consultation with your treating physician. Diagnosis confirmation (flow cytometry for PNH; clinical and complement/ADAMTS13 criteria for aHUS; AChR-antibody for gMG; AQP4-IgG for NMOSD), and clinical rationale.
- Meningococcal vaccination / prophylaxis. Vaccination at least 2 weeks before first dose, or appropriate antibiotic cover per labeling.
- MoHAP named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner, aligned with the manufacturer's controlled-distribution model.
- Cold-chain shipment. Soliris ships at 2-8°C with continuous temperature monitoring.
- Arrival, induction, and maintenance dosing. The infusion facility administers on the induction-then-biweekly schedule.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming indication, diagnostic evidence, prior therapies, and Soliris as the indicated treatment
- Verification of the UAE medical licence
- Patient identifier
- Meningococcal vaccination documentation or prophylaxis plan
- Planned induction and biweekly maintenance regimen
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for complement inhibitors, including the meningococcal-infection risk-minimisation block.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. International cold-chain logistics, MoHAP documentation handling, and coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Maintenance doses ship on a rolling biweekly basis.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Soliris specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody and aligned with the manufacturer's controlled-distribution program.
- Documentation. Regulatory package for your physician and for MoHAP review, including the meningococcal-risk-minimisation block.
- Logistics. Cold-chain, temperature-monitored shipment.
- Dedicated case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation and respect for the manufacturer's controlled-distribution expectations.
What about the meningococcal warning? It is load-bearing. Vaccination at least 2 weeks before first dose, or antibiotic prophylaxis per labeling, is non-negotiable. Your physician coordinates this before treatment starts.
Is Ultomiris an alternative? Yes, Ultomiris (ravulizumab) is a longer-interval C5 inhibitor in the same family, dosed every eight weeks. Your physician will choose between them based on clinical profile, prior exposure, and logistics.
Will private insurance cover this? Cash-pay is the default. Some UAE insurers reimburse named-patient imports for ultra-rare-disease therapies on escalated review; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Soliris coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Soliris in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Soliris for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Soliris in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Soliris. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Soliris in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Soliris to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Soliris to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Soliris in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Soliris in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.